Will resume COVID-19 vaccine trials after DCGI nod: Serum Institute - (The Economic Times via NewsPoints Desk)

  • Serum Institute of India (SII) said it will resume clinical trials of AstraZeneca's COVID-19 vaccine candidate after getting the permission from the Drugs Controller General of India (DCGI), as reported The Economic Times.

  • AstraZeneca said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that the trials were safe.

  • "Once DCGI will give us the permission to restart the trials in India, we will resume the trials," SII said.

To read more NewsPoints articles, click here.